UNLABELLED: Melanoma continues to be a major health problem with no effective therapy. Melanocytes, both benign and malignant, express many anti-apoptotic factors. Survivin is a member of the family of inhibitors of apoptosis proteins (IAP) and is preferentially expressed in tumor cells, including melanoma. YM155 is a small molecule suppressant of survivin that has been shown in preclinical cell lines, xenograft models and phase I studies to have anti-tumor activity. METHODS: This was an open-label, multi-center, study of YM155 monotherapy in subjects with unresectable stage III or IV melanoma. Thirty-four chemotherapy naïve subjects were treated with YM155 at a dose of 4.8 mg/m(2)/day administered by continuous infusion for 168-hours (7 days) followed by a 14-day rest period, for up to 6 cycles or until disease progression. RESULTS: One subject had a partial response to treatment seen at cycle two and lasting through cycle eight. Median progression-free survival was 1.3 months (95% CI; 1.3-2.7). Median overall survival was 9.9 months (95% CI; 7.0-14.5). Overall, YM155 was well tolerated with the most common (>20%) adverse events reported as fatigue, nausea, pyrexia, headache, arthralgia and back pain. Only four subjects required dose reductions. CONCLUSIONS: YM155 was well tolerated in subjects with advanced melanoma; however, the pre-specified primary end-point for efficacy which required two responders in 29 evaluable subjects was not achieved.
UNLABELLED: Melanoma continues to be a major health problem with no effective therapy. Melanocytes, both benign and malignant, express many anti-apoptotic factors. Survivin is a member of the family of inhibitors of apoptosis proteins (IAP) and is preferentially expressed in tumor cells, including melanoma. YM155 is a small molecule suppressant of survivin that has been shown in preclinical cell lines, xenograft models and phase I studies to have anti-tumor activity. METHODS: This was an open-label, multi-center, study of YM155 monotherapy in subjects with unresectable stage III or IV melanoma. Thirty-four chemotherapy naïve subjects were treated with YM155 at a dose of 4.8 mg/m(2)/day administered by continuous infusion for 168-hours (7 days) followed by a 14-day rest period, for up to 6 cycles or until disease progression. RESULTS: One subject had a partial response to treatment seen at cycle two and lasting through cycle eight. Median progression-free survival was 1.3 months (95% CI; 1.3-2.7). Median overall survival was 9.9 months (95% CI; 7.0-14.5). Overall, YM155 was well tolerated with the most common (>20%) adverse events reported as fatigue, nausea, pyrexia, headache, arthralgia and back pain. Only four subjects required dose reductions. CONCLUSIONS: YM155 was well tolerated in subjects with advanced melanoma; however, the pre-specified primary end-point for efficacy which required two responders in 29 evaluable subjects was not achieved.
Authors: M R Middleton; J J Grob; N Aaronson; G Fierlbeck; W Tilgen; S Seiter; M Gore; S Aamdal; J Cebon; A Coates; B Dreno; M Henz; D Schadendorf; A Kapp; J Weiss; U Fraass; P Statkevich; M Muller; N Thatcher Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Nele Kindt; Axel Menzebach; Marlies Van de Wouwer; Inge Betz; Astrid De Vriese; Edward M Conway Journal: FASEB J Date: 2007-09-05 Impact factor: 5.191
Authors: Edward L Korn; Ping-Yu Liu; Sandra J Lee; Judith-Anne W Chapman; Donna Niedzwiecki; Vera J Suman; James Moon; Vernon K Sondak; Michael B Atkins; Elizabeth A Eisenhauer; Wendy Parulekar; Svetomir N Markovic; Scott Saxman; John M Kirkwood Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: Anthony W Tolcher; Alain Mita; Lionel D Lewis; Christopher R Garrett; Elizabeth Till; Adil I Daud; Amita Patnaik; Kyri Papadopoulos; Chris Takimoto; Pamela Bartels; Anne Keating; Scott Antonia Journal: J Clin Oncol Date: 2008-09-29 Impact factor: 50.717
Authors: Qiuying Cheng; Xiang Ling; Andrew Haller; Takahito Nakahara; Kentaro Yamanaka; Aya Kita; Hiroshi Koutoku; Masahiro Takeuchi; Michael G Brattain; Fengzhi Li Journal: Int J Biochem Mol Biol Date: 2012-05-18
Authors: Bing Z Carter; Yihua Qiu; Xuelin Huang; Lixia Diao; Nianxiang Zhang; Kevin R Coombes; Duncan H Mak; Marina Konopleva; Jorge Cortes; Hagop M Kantarjian; Gordon B Mills; Michael Andreeff; Steven M Kornblau Journal: Blood Date: 2012-05-29 Impact factor: 22.113
Authors: Nicholas R Galloway; Carlos J Diaz Osterman; Karl Reiber; Jessica M S Jutzy; Fengzhi Li; Guangchao Sui; Ubaldo Soto; Nathan R Wall Journal: Biochem Biophys Res Commun Date: 2014-02-04 Impact factor: 3.575
Authors: Jessica L F Teh; Timothy J Purwin; Evan J Greenawalt; Inna Chervoneva; Allison Goldberg; Michael A Davies; Andrew E Aplin Journal: Cancer Res Date: 2016-08-03 Impact factor: 12.701
Authors: Paolo A Ascierto; Antonio M Grimaldi; Ana Carrizosa Anderson; Carlo Bifulco; Alistair Cochran; Claus Garbe; Alexander M Eggermont; Mark Faries; Soldano Ferrone; Jeffrey E Gershenwald; Thomas F Gajewski; Ruth Halaban; F Stephen Hodi; Richard Kefford; John M Kirkwood; James Larkin; Sancy Leachman; Michele Maio; Richard Marais; Giuseppe Masucci; Ignacio Melero; Giuseppe Palmieri; Igor Puzanov; Antoni Ribas; Yvonne Saenger; Bastian Schilling; Barbara Seliger; David Stroncek; Ryan Sullivan; Alessandro Testori; Ena Wang; Gennaro Ciliberto; Nicola Mozzillo; Francesco M Marincola; Magdalena Thurin Journal: J Transl Med Date: 2014-10-28 Impact factor: 5.531